Research programme: gene therapies - SalioGen Therapeutics
Latest Information Update: 02 Aug 2021
At a glance
- Originator SalioGen Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Hyperlipoproteinaemia type IIa